Diabetes, Cardiovascular Risks, and Lipoproteins — Research Topic | NobleBlocks | NobleBlocks

Diabetes, Cardiovascular Risks, and Lipoproteins

Top publications in Diabetes, Cardiovascular Risks, and Lipoproteins across the NobleBlocks index. Open any paper for its abstract, citations, and AI-generated take.

Indexed papers

1.3K

Total citations

4.4K

Latest paper

2025

Papers per year (last 16 years) — click a bar to see papers from that year

20102025

Top papers

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Brian A. Ference, Henry N. Ginsberg, Ian Graham, Kausik K. Ray +22 more

2017· European Heart Journal3.3K

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi, Jonathan Afilalo +14 more

2015· Journal of the American Society of Echocardiography11.5K

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett +8 more

2015· New England Journal of Medicine10.3K

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

Gregory A. Roth, George A. Mensah, Catherine O. Johnson, Giovanni Addolorato +196 more

2020· Journal of the American College of Cardiology9.6K

Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

Alan S. Go, Glenn M. Chertow, Dongjie Fan, Charles E. McCulloch +1 more

2004· New England Journal of Medicine9.4K

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas +150 more

2019· European Heart Journal7.5K

European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham +24 more

2012· International journal of behavioral medicine7.4K

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

2000· New England Journal of Medicine6.6K

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw +6 more

2017· New England Journal of Medicine6.6K

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen +11 more

2016· New England Journal of Medicine6.3K

General Cardiovascular Risk Profile for Use in Primary Care

Ralph B. D’Agostino, Ramachandran S. Vasan, Michael J. Pencina, Philip A. Wolf +3 more

2008· Circulation6.3K

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, William F. Keane +6 more

2001· New England Journal of Medicine5.9K

Particulate Matter Air Pollution and Cardiovascular Disease

Robert D. Brook, Sanjay Rajagopalan, C. Arden Pope, Jeffrey R. Brook +11 more

2010· Circulation5.7K

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Massimo F. Piepoli, Arno W. Hoes, Stefan Agewall, Christian Albus +22 more

2016· European Heart Journal5.6K

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz +11 more

2016· New England Journal of Medicine5.5K

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

David C Goff, Donald M Lloyd-Jones, Glen Bennett, Sean Coady +32 more

2014· Circulation5.5K

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo +129 more

2021· European Heart Journal5.5K

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon +16 more

2019· New England Journal of Medicine5.4K

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1998· New England Journal of Medicine5.3K

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Marc S. Sabatine, Robert P. Giugliano, Anthony C. Keech, Narimon Honarpour +8 more

2017· New England Journal of Medicine5.3K

Search all 1.3K papers in Diabetes, Cardiovascular Risks, and Lipoproteins →

Explore this topic

Search all papers Explore in Research Start a literature review ← Browse all topics

Topic snapshot

1.3K papers indexed

4.4K total citations

Latest: 2025